Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR mCRC
NCT05160727Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in colorectal cancer (CRC), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05160727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05160727.